Download PDF
Thromb Haemost 1990; 63(03): 459-463
DOI: 10.1055/s-0038-1645066
Original Article
Schattauer GmbH Stuttgart

Interaction of a Plasmin A-Chain/t-PA B-Chain Hybrid Enzyme with Plasma Inhibitors In Vivo and In Vitro

S Wilson
The Department of Biotechnology, SmithKline Beecham, Great Burgh, Epsom, Surrey, UK
,
P Chamberlain
The Department of Biotechnology, SmithKline Beecham, Great Burgh, Epsom, Surrey, UK
,
I Dodd
The Department of Biotechnology, SmithKline Beecham, Great Burgh, Epsom, Surrey, UK
,
A Esmail
The Department of Biotechnology, SmithKline Beecham, Great Burgh, Epsom, Surrey, UK
,
J H Robinson
The Department of Biotechnology, SmithKline Beecham, Great Burgh, Epsom, Surrey, UK
› Author Affiliations
Further Information

Publication History

Received 15 September 1989

Accepted after revision 23 January 1990

Publication Date:
30 June 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

A hybrid plasminogen activator consisting of the “A” chain of plasmin linked to the “B” chain of rt-PA was inhibited in vitro in human and guinea pig plasmas 4 to 5-fold more rapidly than its parent activator, two-chain t-PA. Using zymographic and autoradiographic techniques together with the use of immunodepleted plasma the major inhibitor was identified as aIpha-2-antiplasmin. The pharmacokinetic profile of the hybrid in guinea pigs was determined by two different methods: disappearance of fibrinolytic activity and removal of radiolabelled hybrid from the circulation. Fibrinolytic activity was cleared rapidly via inhibitory mechanisms, whilst radiolabelled material was cleared considerably more slowly due to the formation of hybrid-inhibitor complexes. When the active site of the hybrid was reversibly acylated inhibitory mechanisms were evaded and a prolonged pharmacokinetic profile of activity was observed.

 

  • References

  • 1 Robinson JH, Dodd I, Esmail A, Ferres H, Nunn B. Slow clearance of acylated, hybrid thrombolytic enzymes. Thromb Haemostas 1988; 59: 421-5
    PubMedSearch in Google Scholar
  • 2 Browne MJ, Carey JE, Chapman CG, Tyrrell AW R, Entwisle C, Lawrence GM P, Reavy B, Dodd I, Esmail A, Robinson JH. A tissue-type plasminogen activator with prolonged clearance in vivo. J Biol Chem 1988; 263: 1599-1602
    PubMedSearch in Google Scholar
  • 3 Browne MJ, Champan CG, Dodd I, Reavy B, Esmail A, Robinson JH. The role of tissue-type plasminogen activator A-chain domains in plasma clearance. Fibrinolysis 1989; 3: 207-14
    PubMedSearch in Google Scholar
  • 4 Larsen GR, Metzger M, Henson K, Blue Y, Horgan P. Pharmacokinetic and distribution analysis of variant forms of tissue-type plasminogen activator with prolonged clearance in rat. Blood 1989; 73: 1842-50
    PubMedSearch in Google Scholar
  • 5 Fu KP, Lees S, Hum WT, Kalyan N, Rappaport R, Hetzel N, Hung PP. Disposition of a novel recombinant tissue plasminogen activator, Δ2-89 t-PA, in mice. Thromb Res 1988; 50: 33-41
    PubMedSearch in Google Scholar
  • 6 Fu PP, Lee S, Hetzel N, Fenichel R, Hum HW, Speth J, Kalyan N, Hung PP. Clearance of a novel recombinant tissue plasminogen activator in rabbits. Thromb Res 1988; 50: 679-85
    CrossrefPubMedSearch in Google Scholar
  • 7 Mohler MA, Tate K, Bringman TS, Fuller G, Keyt B, Vehar G, Hotchkiss AJ. Circulatory metabolism of recombinant tissue-type plasminogen activator in monkeys and rabbits. Fibrinolysis 1988; 2: 17-23
    PubMedSearch in Google Scholar
  • 8 Seifried E, Tanswell P, Rijken DC, Barrett-Bergshoeff MM, Su C AP F, Kluft C. Pharmacokinetics of antigen and activitv of recombinant tissue-type plasminogen activator after infusion in healthy volunteers. Arzneim Forsch 1988; 38: 418-22
    PubMedSearch in Google Scholar
  • 9 Browne MJ, Dodd I, Carey JE, Chapman cG, Robinson JH. Increased yield of human tissue-type plasminogen activator obtained by means of recombinant DNA technology. Thromb Haemostas 1985; 54: 422-4
    PubMedSearch in Google Scholar
  • 10 Dodd I, Fears R, Robinson JH. Isolation and preliminary characterisation of active B-chain of recombinant tissue-type plasminogen activator. Thromb Haemostas 1986; 55: 94-7
    PubMedSearch in Google Scholar
  • 11 Fraker PJ, Speck JC. Protein and cell membrane iodinations with a sparingly soluble chloramide 1, 3, 4, 6-tetrachloro-3 a, 6a-Dipheny-Iglycoluril. Biochem Biophys Res Commun 1978; 80: 849-57
    CrossrefPubMedSearch in Google Scholar
  • 12 Lacmmli UK. Cleavage of structural proteins during the assembly of the head of Bacteriophage T4. Nature 1970; 227: 680-5
    CrossrefPubMedSearch in Google Scholar
  • 13 Granelli-Piperno A, Reich E. A study of proteases and protease-inhibitor complexes in biological fluids. J Exp Med 1978; 148: 223-34
    CrossrefPubMedSearch in Google Scholar
  • 14 Sprengers ED, Kluft C. Plasminogen activator inhibitors. Blood 1987; 69: 381-7
    PubMedSearch in Google Scholar
  • 15 Wiman B, Collen D. On the kinetics of the reaction between human antiplasmin and plasmin. Eur J Biochem 1978; 84: 573-8
    CrossrefPubMedSearch in Google Scholar
  • 16 Haggroth L, Mattsson Ch, Friberg J. Inhibition of the tissue plasminogen acctivator in plasma from different species. Thromb Res 1984; 33: 583-94
    CrossrefPubMedSearch in Google Scholar
  • 17 Korninger C, Collen D. Neutralisation of human extrinsic (tissue-type) plasminogen activator in human plasma: no evidence for a specific inhibitor. Thromb Haemostas 1981; 46: 662-5
    PubMedSearch in Google Scholar
  • 18 The AIMS trial Study Group. Effect of intravenosus APS AC on mortality after acute myocardial infarction. Preliminary report of a placebo-controlled trial. Lancet 1988; i: 545-9
    PubMedSearch in Google Scholar